Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 29, 2017

DrugPatentWatch Database Preview

Fluticasone propionate; salmeterol xinafoate - Generic Drug Details

« Back to Dashboard

What are the generic sources for fluticasone propionate; salmeterol xinafoate and what is the scope of fluticasone propionate; salmeterol xinafoate freedom to operate?

Fluticasone propionate; salmeterol xinafoate
is the generic ingredient in five branded drugs marketed by Glaxo Grp Ltd and Teva Pharm, and is included in three NDAs. There are thirty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fluticasone propionate; salmeterol xinafoate has four hundred and nine patent family members in fifty-seven countries.

There are twenty-two drug master file entries for fluticasone propionate; salmeterol xinafoate. Eleven suppliers are listed for this compound.

Summary for Generic Name: fluticasone propionate; salmeterol xinafoate

Drug Master File Entries: see list22
Suppliers / Packagers: see list11
Clinical Trials: see list207
Drug Prices:see low prices
DailyMed Link:fluticasone propionate; salmeterol xinafoate at DailyMed

Pharmacology for Ingredient: fluticasone propionate; salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-002Jun 8, 2006RXYesYes6,170,717*PED► SubscribeY► Subscribe
Glaxo Grp Ltd
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION021077-001Aug 24, 2000RXYesYes5,873,360*PED► Subscribe ► Subscribe
Glaxo Grp Ltd
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-001Jun 8, 2006RXYesYes7,107,986*PED► SubscribeY► Subscribe
Teva Pharm
fluticasone propionate; salmeterol xinafoate
POWDER;INHALATION208799-002Jan 27, 2017RXYesNo8,978,966► SubscribeY ► Subscribe
Glaxo Grp Ltd
fluticasone propionate; salmeterol xinafoate
AEROSOL, METERED;INHALATION021254-001Jun 8, 2006RXYesYes6,315,173*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Formulary management
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus